Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 160Myelodysplastic Syndromes 44Leukemia, Myelomonocytic, Chronic 25Leukemia 16Myeloproliferative Disorders 11Recurrence 9Hematologic Neoplasms 8Neoplasms 6Lymphoma, T-Cell, Peripheral 6Primary Myelofibrosis 5Leukemia, Biphenotypic, Acute 5Anemia, Refractory, with Excess of Blasts 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Monocytic, Acute 4Hematologic Diseases 4GATA2 Deficiency 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Polycythemia Vera 2Lymphoma, T-Cell 2

Interventions

Cyclophosphamide 12Specimen Handling 9cabozantinib 8X-Rays 8Magnetic Resonance Spectroscopy 8fludarabine 7Phantoms, Imaging 7Biopsy 7Temozolomide 6Gemcitabine 5regorafenib 4pembrolizumab 4Vincristine 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methotrexate 4Doxorubicin 4olaparib 3irinotecan sucrosofate 3fludarabine phosphate 3dinutuximab 3Zoledronic Acid 3Surveys and Questionnaires 3Irinotecan 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Azacitidine × 1 year × Clear all
NCT03628209 2026-02-05

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
21 enrolled
Sarcoma

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡